IGC Pharma, Inc. — Form 10-Q Summary
Reporting period: Three and six months ended September 30, 2023 (the company’s fiscal second quarter and first half of fiscal 2024). Financial amounts below are in U.S. dollars, in thousands, unless stated otherwise. Interim statements are unaudited.
Business context
IGC is a clinical-stage pharmaceutical company developing five assets targeting Alzheimer’s disease, including IGC-AD1, its most advanced candidate. It also sells women’s wellness products and white-label formulations, and operates an infrastructure business involving construction contracts and heavy-equipment rentals.
IGC-AD1 is in a Phase 2B, randomized, double-blind, placebo-controlled trial for agitation associated with Alzheimer’s dementia. The trial is designed for 146 participants at 10 U.S. and Canadian sites, with treatment over six weeks. The company also reports four other Alzheimer’s-related assets at varying development stages.
Financial performance and position
| Metric | Three months ended September 30 | Six months ended September 30 |
|---|---|---|
| Revenue, 2023 / 2022 | $291 / $202; up 44% | $846 / $414; up 104% |
| Gross profit, 2023 / 2022 | $174 / $135 | $429 / $277 |
| Gross margin, 2023 / 2022 | 60% / 67% | 51% / 67% |
| Operating loss, 2023 / 2022 | $(2,491) / $(2,488) | $(4,630) / $(5,290) |
| Net loss, 2023 / 2022 | $(2,451) / $(2,442) | $(4,526) / $(5,227) |
| Basic and diluted loss per share | $(0.05) / $(0.05) | $(0.08) / $(0.10) |
- Quarterly revenue growth came mainly from white-label services: $222 versus $45 a year earlier. Wellness and lifestyle revenue fell to $69 from $150; infrastructure revenue was nil versus $7.
- For the six-month period, white-label revenue increased to $567 from $167, and infrastructure revenue rose to $166 from $17, primarily reflecting completion of a construction contract. Wellness and lifestyle revenue declined to $113 from $230.
- Quarterly SG&A decreased 25% to $1,397, while R&D increased 65% to $1,268, primarily due to IGC-AD1 Phase 2 work and preclinical studies. For the six months, SG&A decreased 11% to $3,044 and R&D decreased 7% to $2,015; the company attributed the R&D reduction mainly to lower non-cash expense.
- At September 30, cash and cash equivalents were $3,026, short-term investments $98, working capital $4,011, total assets $16,506, and total liabilities $2,408. Cash was $3,196 and working capital $4,568 at March 31, 2023.
- Six-month operating cash use was $3,086, compared with $3,882 a year earlier. Investing activities provided $67 and financing activities provided $2,858; cash declined by $170 to $3,026.
- Debt was limited: $139 of long-term EIDL loan debt, plus approximately $3 of short-term loan balance. A $12 million O-Bank credit facility was available but undrawn at September 30; it matures June 30, 2024, with an option to renew.
- The company issued 10 million shares at $0.30 per share in a private placement, generating approximately $3 million gross and $2.86 million net proceeds. Shares outstanding increased from 53.1 million at March 31 to 63.7 million at September 30.
Changes, outlook, and risks
- Management says available cash, the working-capital credit facility, and equity investment are expected to support operations beyond the twelve months following issuance of the statements. It cautions that estimates depend on assumptions and capital could be used sooner than expected. The company remains unprofitable and expects significant operating losses and negative operating cash flow in the near future.
- Management plans to seek further financing, including private placements, ATM offerings, and potentially non-dilutive funding. On October 27, after quarter-end, IGC entered into a sales agreement permitting up to $60 million of common-stock sales, subject to limitations. Future equity financing may dilute shareholders; the filing gives no specific revenue, profit, or cash-flow guidance.
- Key risks include clinical-trial delay or failure, insufficient resources to complete trials or commercialize products, regulatory approval and FDA policy uncertainty for hemp-based products, patent and intellectual-property risk, and changes in pricing or regulation. The company’s results are highly dependent on clinical outcomes; there is no assurance of efficacy or commercialization.
- Gross margins are subject to product and segment mix, and management says revenue is insufficient to project margins. Six-month margin fell to 51% from 67%, reflecting revenue mix changes.
- The Apogee litigation was resolved following a court ruling largely favorable to IGC; the case was dismissed in its entirety on October 6, 2023. The court’s ruling included Apogee’s breach of contract and IGC’s entitlement to damages and interest. IGC also cancelled 500,000 returned shares.
- Subsequent developments included an October 8 European patent grant concerning a cannabinoid composition and pain treatment. The filing also reports a Canadian patent issued July 11. These patent disclosures do not establish regulatory approval or commercial effectiveness.
- Management reported effective disclosure controls and no material changes in internal control over financial reporting during the quarter.
Most important facts for investors to verify
- Progress, enrollment, safety findings, and eventual results of the IGC-AD1 Phase 2B trial, and the company’s funding needs to complete it.
- Whether white-label revenue growth is sustainable, given the decline in branded wellness sales and the small revenue base.
- Cash burn, access and terms of the undrawn $12 million facility, and actual use of the post-quarter $60 million stock-sale program.
- Potential dilution from financing and outstanding equity awards; the filing reports approximately 9 million granted but unissued restricted share units.
- Collectability of $947 in claims receivable, which management says may be challenging within the next 12 months, including $140 owed by a manufacturer.
- Whether patent rights, clinical findings, and management’s stated cash runway translate into regulatory approval, product sales, and sustained liquidity.